Touyun Biotech Details Financing and Asset Moves to Address Audit Qualification and Support Growth
I'm PortAI, I can summarize articles.
Touyun Biotech Group Limited has announced measures to address an audit disclaimer and support growth, including expanding its health products portfolio and strengthening distribution channels. The company has secured a sales consortium commitment to purchase RMB1 billion of products and deferred repayments of HK$121.8 million from stakeholders. Additionally, it has obtained over HK$54 million in new loans and is negotiating extensions on existing loans. These actions aim to stabilize working capital and reduce audit qualifications. The latest analyst rating for the stock is a Sell with a price target of HK$0.20.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments